
This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.

In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
Explore the mechanism of disease of bullous pemphigoid (BP), including the roles of autoimmunity and type 2 inflammation, in this informative video.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Dr. Donna Culton discusses biomarkers in bullous pemphigoid and considers their potential clinical use.
An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.